Diffractive Implantable Phakic Contact Lens, Three Years After Surgery: A Refractive Stability And Safety Study

To evaluate safety and the refractive stability in myopic-presbyopic patients operated with Diffractive Implantable Phakic Contact Lens (IPCL), comparing the postoperative results between the first and third year.

Dr Nano Eye Clinic, Olivos (Buenos Aires) Argentina.

A retrospective case-series study was conducted, encompassing all myopic-presbyopic patients who underwent surgery with the diffractive IPCL V2.0 intraocular lens (Care Group, India) between December 2019 and December 2021, with a minimum follow-up of 36 months. The following main outcomes were registered and compared between the first and third postoperative year: spherical equivalent (SE), uncorrected distance (UDVA), intermediate (UIVA) at 66 cm, and near visual acuity (UNVA) at 32 cm were monitored, emphasizing visual acuity stability; safety assessments including endothelial cell density (ECD), intraocular pressure (IOP), vault measurements, and cataract formation were evaluated.

A total of 64 eyes from 32 patients (age: 45.2 ±2.3 years) were evaluated. The data compared (versus: vs) between the first and third postoperative year, respectively, and their statistical significance are described below. SE: -0.09± 0.33D vs -0.09± 0.33D (p: 0.12); UDVA: 0.02 ±0.07 vs 0.02 ±0.07 (p: 0.15); UIVA (66 cm) 0.04 ±0.07 vs 0.05 ±0.06 (p 0.13); UNVA (32 cm) 0.09 ±0.07 vs 0.09 ±0.05; IOP 13.7 ±1.2 mmHg vs 13.6 ±1.2 (p: 0.14); ECD 2622.0 ±219.3 vs 2611.5 ±215.7 (p: 0.18); Vault: 537.7 ± 101.1 vs  534.3 ± 99.5 (p: 0.11). No cases of visually significant cataract formation or lens explantation have occurred.

Myopic-presbyopic patients implanted with diffractive IPCL achieved safe and effective outcomes that remain stable three years after surgery.